***JBR Clinical Research is not accepting new applicants for this study at this time. If you would like to be considered for other studies, please submit a form on our Healthy Volunteers Study page or call us at 801-261-2000. Thank you!***
JBR Clinical Research is conducting a clinical research study for an investigational Chronic Idiopathic Constipation medication study. For individuals 18-75.
Participants that are selected for the study will receive a no cost investigational medication, health care related to the study, and compensation up to $300 for time and travel.
Basic qualifications are:
- Male or Female
- Must have Chronic Idiopathic Constipation
If you qualify you may receive:
- Study related exam
- No cost investigational medication
- Compensation up to $300 for time and travel related to the study
What is Chronic Idiopathic Constipation?
Idiopathic or functional constipation is a common disorder, affecting approximately 15% of the population of the United States of America (USA) depending on demographic factors and the definitions used.
Constipation is a symptom of many diseases and is a collective term, used to imply infrequent stools, incomplete bowel movements (BMs), straining, bloating, and hard lumpy stool.2 Treatment of constipation is usually based on increased dietary fiber and supplementation with bulking agents, exercise, and habit training.
However, often only partial relief is obtained, and the majority of patients use non-bulking laxatives on a regular basis without medical supervision. Chronic use of non-bulking laxatives is often inappropriate, and may lead to side effects, such as dependency and progressive tolerance, electrolyte imbalance, and, for the anthraquinones, melanosis coli.
In addition, stimulant laxatives may damage the myenteric plexus, resulting in cathartic colon. A more appropriate approach to the therapy of constipation consists of physiologically stimulating intestinal motility.
As such, plecanatide has been shown to increase fluid secretion and facilitate BMs. Plecanatide, by increasing fluid secretion, may be an appropriate treatment for patients with Chronic Idiopathic Constipation (CIC). The mechanism of action of plecanatide is completely distinguishable from serotonergic agents.
Thus, plecanatide is expected to be a member of a new class of oral therapeutic agents used to improve current therapy of CIC.